1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (310) 423-0155
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Improved survival in women with BRCA-associated ovarian carcinoma†
Article first published online: 17 APR 2003
DOI: 10.1002/cncr.11310
Copyright © 2003 American Cancer Society
Additional Information
How to Cite
Cass, I., Baldwin, R. L., Varkey, T., Moslehi, R., Narod, S. A. and Karlan, B. Y. (2003), Improved survival in women with BRCA-associated ovarian carcinoma. Cancer, 97: 2187–2195. doi: 10.1002/cncr.11310
- †
See related editorial on pages 2127–9, this issue.
Publication History
- Issue published online: 17 APR 2003
- Article first published online: 17 APR 2003
- Manuscript Accepted: 18 DEC 2002
- Manuscript Revised: 9 DEC 2002
- Manuscript Received: 11 NOV 2002
Funded by
- Gynecologic Cancer Foundation/Susan G. Komen Breast Cancer Foundation
- American Cancer Society, California Division Inc.. Grant Number: 5-3-00
- Cedars-Sinai Research for Womens Cancers
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1
- 2, , , A DNA Repair Pathway-Focused Score for Prediction of Outcomes in Ovarian Cancer Treated With Platinum-Based Chemotherapy, JNCI Journal of the National Cancer Institute, 2012, 104, 9, 670
- 3, , , , , , , , , , , , BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma, Modern Pathology, 2012, 25, 5, 740
- 4, , , , , , , , , , , Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival, Cancer Genetics, 2012, 205, 1-2, 34
- 5, , , , , , Clinicopathologic Characteristics and Survival in BRCA1- and BRCA2-Related Adnexal Cancer, International Journal of Gynecological Cancer, 2012, 22, 4, 579
- 6, , Genetic Risk and Gynecologic Cancers, Hematology/Oncology Clinics of North America, 2012, 26, 1, 13
- 7, , Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology, Translational Research, 2012,
- 8, , , Immunohisochemical study of BRCA1, BRCA2, and poly (ADP-ribose) polymerase-1 in ovarian tumors, Korean Journal of Obstetrics & Gynecology, 2012, 55, 1, 8
- 9, , , , , , , , , , , , , Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer, Cancer, 2012, 118, 11Direct Link:
- 10, , , Management of borderline ovarian tumours, The Obstetrician & Gynaecologist, 2012, 14, 2Direct Link:
- 11, , , , , Role of common genetic variants in ovarian cancer susceptibility and outcome: progress to date from the ovarian cancer association consortium (OCAC), Journal of Internal Medicine, 2012, 271, 4Direct Link:
- 12, , Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes, Future Medicinal Chemistry, 2012, 4, 1, 51
- 13, , Tumour heterogeneity and drug resistance: Personalising cancer medicine through functional genomics, Biochemical Pharmacology, 2012, 83, 8, 1013
- 14
- 15, , , , , , , , , , A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer, Gynecologic Oncology, 2011, 123, 3, 486
- 16, , , , , , , , , , , , BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer, Gynecologic Oncology, 2011, 123, 3, 492
- 17, , , , , , , , , , , Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients, Annals of Oncology, 2011, 22, 6, 1346
- 18
- 19, , Drug therapy for hereditary cancers, Hereditary Cancer in Clinical Practice, 2011, 9, 1, 5
- 20, , , , , , Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells, BMC Pharmacology, 2011, 11, 1, 7
- 21, , , , , , , , , , , , , , , , ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma, Cancer, 2011, 117, 15Direct Link:
- 22, , , , , , , , , , Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer, Gynecologic Oncology, 2011, 121, 2, 353
- 23, , , , , , , , , , , , , , , , , , , , , Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations, Gynecologic Oncology, 2011, 121, 2, 358
- 24, , PARP Inhibitor Treatment in Ovarian and Breast Cancer, Current Problems in Cancer, 2011, 35, 1, 7
- 25
- 26, , Pattern and chemosensitivity of ovarian cancer in patients with BRCA1/2 mutations, Journal of Obstetrics & Gynaecology, 2011, 31, 2, 178
- You have free access to this content27, , , , Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic, CA: A Cancer Journal for Clinicians, 2011, 61, 1Direct Link:
- You have free access to this content28, , Recent progress in the diagnosis and treatment of ovarian cancer, CA: A Cancer Journal for Clinicians, 2011, 61, 3Direct Link:
- You have free access to this content29, , , Secondary mutations of BRCA1/2 and drug resistance, Cancer Science, 2011, 102, 4Direct Link:
- 30, , Survivorship as an Element of Clinical Trials in Ovarian Cancer, International Journal of Gynecological Cancer, 2011, 21, 4, 788
- 31, , , Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer, Cancer Genetics, 2011, 204, 10, 525
- 32, , Translational application of epigenetic alterations: Ovarian cancer as a model, FEBS Letters, 2011, 585, 13, 2112
- 33
- 34
- 35, , , , A critical re-appraisal of BRCA1 methylation studies in ovarian cancer, Gynecologic Oncology, 2010, 119, 2, 376
- You have free access to this content36, , , , , , , , , , , , BRCA1 and XRCC1 polymorphisms associated with survival in advanced gastric cancer treated with taxane and cisplatin, Cancer Science, 2010, 101, 5Direct Link:
- 37, , , , , , , , , BRCA1/2 Germline Mutations in Jewish Patients With Uterine Serous Carcinoma, International Journal of Gynecological Cancer, 2010, 20, 7, 1148
- 38, , Cancer genetics and reproduction, Best Practice & Research Clinical Obstetrics & Gynaecology, 2010, 24, 1, 3
- 39, , , Cisplatin Affects the Conformation of Apo Form, not Holo Form, of BRCA1 RING Finger Domain and Confers Thermal Stability, Chemistry & Biodiversity, 2010, 7, 8Direct Link:
- 40
- 41, , Fine tuning chemotherapy to match BRCA1 status, Biochemical Pharmacology, 2010, 80, 5, 647
- 42, , , Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2, Genetics in Medicine, 2010, 12, 5, 245
- 43, , , Making the best of PARP inhibitors in ovarian cancer, Nature Reviews Clinical Oncology, 2010, 7, 9, 508
- 44, , , Microenvironment and Pathogenesis of Epithelial Ovarian Cancer, Hormones and Cancer, 2010, 1, 6, 277
- 45, , , , , , Moving Toward Personalized Medicine, International Journal of Gynecological Cancer, 2010, 20, 5, 704
- 46, , , , , , , , , , Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube, Gynecologic Oncology, 2010, 118, 3, 299
- 47, , , , , BRCA1 and implications for response to chemotherapy in ovarian cancer, Gynecologic Oncology, 2009, 113, 1, 134
- 48, , , , , , , , Does Paclitaxel-Carboplatin Chemotherapy in a Dose-Dense Regimen Enhance Survival of BRCA-Related Ovarian Cancer Patients?, International Journal of Gynecological Cancer, 2009, 19, 9, 1501
- 49, , , , , , , , , , Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer, Gynecologic Oncology, 2009, 115, 2, 209
- 50, , , , , , , , , , , Family History of Cancer Rather Than p53 Status Predicts Efficacy of Pegylated Liposomal Doxorubicin and Oxaliplatin in Relapsed Ovarian Cancer, International Journal of Gynecological Cancer, 2009, 19, 6, 1022
- 51, Hereditary ovarian cancer: biology, response to chemotherapy and prognosis, Women's Health, 2009, 5, 5, 543
- 52, , , , , , , Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management, Molecular Oncology, 2009, 3, 2, 97
- 53, , , Impaired DNA damage response — An Achilles' heel sensitizing cancer to chemotherapy and radiotherapy, European Journal of Pharmacology, 2009, 625, 1-3, 143
- 54, Molecular profiles of hereditary epithelial ovarian cancers and their implications for the biology of this disease, Molecular Oncology, 2009, 3, 2, 151
- 55, , , , Proteogenomic studies in epithelial ovarian cancer: established knowledge and future needs, Biomarkers in Medicine, 2009, 3, 6, 743
- 56
- 57, , , , , Timing of BRCA1/BRCA2 genetic testing in women with ovarian cancer, Genetics in Medicine, 2009, 11, 9, 624
- 58, , , , , , , , , , , , , Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy, International Journal of Cancer, 2009, 124, 6Direct Link:
- 59, , Attitude pratique devant une famille à haut risque de cancer du sein et/ou de l’ovaire : le point de vue de l’endocrinologue, Annales d'Endocrinologie, 2008, 69, 3, 193
- 60, , , , , , , , , , , Genomic and proteomic characterization of YDOV-157, a newly established human epithelial ovarian cancer cell line, Molecular and Cellular Biochemistry, 2008, 319, 1-2, 189
- 61, , , , , , , , , High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland, Gynecologic Oncology, 2008, 108, 2, 433
- 62, , , , Multiple diseases in carrier probability estimation: Accounting for surviving all cancers other than breast and ovary in BRCAPRO, Statistics in Medicine, 2008, 27, 22Direct Link:
- 63
- 64, , , , Prolonged survival among women with BRCA germline mutations and advanced endometrial cancer: a case series, International Journal of Gynecological Cancer, 2008, 18, 3Direct Link:
- 65, , , , , , , , , Resistance to therapy caused by intragenic deletion in BRCA2, Nature, 2008, 451, 7182, 1111
- 66, , , , , , , , , , Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients, Breast Cancer Research and Treatment, 2008, 115, 2, 359
- 67, , The clinical management of BRCA1 and BRCA2 mutation carriers, Current Oncology Reports, 2008, 10, 1, 47
- 68, , , , , , , , , , , , , , , , , , , , , The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro, British Journal of Cancer, 2008, 98, 6, 1085
- 69, , , The effect of symptom duration in epithelial ovarian cancer on prognostic factors, Archives of Gynecology and Obstetrics, 2008, 279, 6, 797
- 70
- 71, , , , Conditional inactivation of Brca1 in the mouse ovarian surface epithelium results in an increase in preneoplastic changes, Experimental Cell Research, 2007, 313, 1, 133
- 72, , , , Epithelial Ovarian Cancer and Low Malignant Potential (LMP) Tumors Associated With a Lower Incidence of Second Primary Breast Cancer, American Journal of Clinical Oncology, 2007, 30, 1, 1
- 73, , , , , , , , , , Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor? The Hellenic Oncology Cooperative Group experience, International Journal of Gynecological Cancer, 2007, 17, 5Direct Link:
- 74, , , Hereditary Ovarian Cancer—Assessing Risk and Prevention Strategies, Obstetrics and Gynecology Clinics of North America, 2007, 34, 4, 651
- 75, , , , , , , High incidence of mutations in BRCA1 and BRCA2 genes in ovarian cancer, Bulletin of Experimental Biology and Medicine, 2007, 144, 1, 83
- 76, , Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome, Nature Clinical Practice Oncology, 2007, 4, 10, 578
- 77, , , , , , , , , , , , Serous fallopian tube carcinoma: A retrospective, multi-institutional case–control comparison to serous adenocarcinoma of the ovary, Gynecologic Oncology, 2007, 107, 3, 398
- 78, , , The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations, Annals of Surgical Oncology, 2007, 15, 1, 21
- 79
- 80
- 81
- 82, , , , , , , , , A polymorphism in the matrix metalloproteinase-1 gene promoter is associated with the prognosis of patients with ovarian cancer, Gynecologic Oncology, 2006, 100, 3, 506
- 83, BRCA1 and BRCA2: Chemosensitivity, Treatment Outcomes and Prognosis, Familial Cancer, 2006, 5, 2, 135
- 84, , , , BRCA1 promoter methylation predicts adverse ovarian cancer prognosis, Gynecologic Oncology, 2006, 101, 3, 403
- 85, , , BRCA1—A good predictive marker of drug sensitivity in breast cancer treatment?, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2006, 1766, 2, 205
- 86
- 87, , , , , , , , Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer, British Journal of Cancer, 2006, 94, 3, 436
- 88, , Guido Fanconi (1892–1979): a jack of all trades, Nature Reviews Cancer, 2006, 6, 11, 893
- 89, Heredity, gender and the discourse of ovarian cancer, New Genetics and Society, 2006, 25, 2, 171
- 90, , , , , , , , , , , , , , Identification et prise en charge des prédispositions héréditaires aux cancers du sein et de l'ovaire (mise à  jour 2004), Pathologie Biologie, 2006, 54, 4, 230
- 91, , , , , Improved survival in BRCA2 carriers with ovarian cancer, Familial Cancer, 2006, 6, 1, 113
- 92, , , , , Molecular predictors of response and outcome in ovarian cancer, Critical Reviews in Oncology/Hematology, 2006, 60, 1, 19
- 93, , , , , , , , , , , Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin-Cohort Study in Ontario, Canada, JNCI Journal of the National Cancer Institute, 2006, 98, 23, 1694
- 94, , , , , , , , , , , , Young Age Is Associated with Favorable Characteristics but Is Not an Independent Prognostic Factor in Patients with Epithelial Ovarian Cancer: A Single Institution Experience, Oncology, 2006, 70, 4, 265
- 95, , , , , , , , , , , , , , , , , A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer, Breast Cancer Research and Treatment, 2005, 96, 1, 97
- 96, , An Achilles' heel for breast cancer?, Nature Structural & Molecular Biology, 2005, 12, 5, 387
- 97, , , , , , BRCA-Mutation–Associated Fallopian Tube Carcinoma, Obstetrics & Gynecology, 2005, 106, 6, 1327
- 98, , , , , , , , , , , , , , BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases, Cancer, 2005, 104, 12Direct Link:
- 99, Clinical implications of the breast cancer susceptibility genesBRCA1andBRCA2, Women's Health, 2005, 1, 1, 27
- 100, , , , , , , , , Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer, Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 0, 139
- 101, , , , , , , , , Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas, Gynecologic Oncology, 2005, 97, 1, 16
- 102, , , , , , Genetic Changes in Ovarian Cancer, Taiwanese Journal of Obstetrics and Gynecology, 2005, 44, 3, 218
- 103, , , Hereditary breast and ovarian cancer: review and future perspectives, Journal of Molecular Medicine, 2005, 84, 1, 16
- 104
- 105, , , , , , Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations, Gynecologic Oncology, 2005, 97, 2, 457
- 106, , , , , , , , Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma, Cancer, 2005, 104, 5Direct Link:
- 107, , , , Prophylaktische Chirurgie des Mamma- und Ovarialkarzinoms, Der Chirurg, 2005, 76, 12, 1145
- 108
- 109, , Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations, Familial Cancer, 2004, 3, 3-4, 265
- 110, Subclassification of Ovarian Surface Epithelial Tumors Based on Correlation of Histologic and Molecular Pathologic Data, International Journal of Gynecological Pathology, 2004, 23, 3, 200
- 111, , , , , The Role of BRCA1 in the Cellular Response to Chemotherapy, JNCI Journal of the National Cancer Institute, 2004, 96, 22, 1659
- 112, , , The use of cytogenetics in understanding ovarian cancer, Biomedicine & Pharmacotherapy, 2004, 58, 1, 17
- 113, BRCA-related ovarian carcinoma, Cancer, 2003, 97, 9Direct Link: